Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s379591
Abstract: Purpose Pyrotinib, a novel human epidermal growth factor receptor 2 (HER2)-targeted tyrosine kinase inhibitor (TKI), has led to remarkable survival outcomes in HER2-positive advanced breast cancer (ABC) in clinical trials and was approved for second-line… read more here.
Keywords: efficacy safety; pyrotinib; study; safety pyrotinib ... See more keywords